Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Acute Coronary Syndromes | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Davis BR, Cutler JA, Gordon D.  et al. for the ALLHAT Research Group.  Rationale and design of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Am J Hypertens.1996;9:342-360.Google Scholar
2.
Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated RegressionNew York, NY: Springer-Verlag; 1997.
3.
Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical Trials. Boca Raton, Fla: Chapman & Hall/CRC Press; 2000.
4.
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials.  Biometrika.1983;70:659-663.Google Scholar
5.
Davis BR, Hardy RJ. Upper bounds for type I and type II error rates in conditional power calculations.  Comm Stat.1990;A19:3571-3584.Google Scholar
6.
Cohn JN, Archibald DG, Ziesche S.  et al.  Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study.  N Engl J Med.1986;314:1547-1552.Google Scholar
7.
Kostis J, Davis BR, Cutler JA.  et al.  Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension.  JAMA.1997;278:212-216.Google Scholar
8.
Hansson L, Lindholm L, Ekbom T.  et al. for the STOP-Hypertension-2 Study Group.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients With Hypertension–2 Study.  Lancet.1999;354:1751-1756.Google Scholar
9.
Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.  Lancet.1997;350:757-764.Google Scholar
10.
Collins R, Peto R, MacMahon S.  et al.  Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.  Lancet.1990;335:827-838.Google Scholar
11.
Hypertension and Detection Follow-up Program Cooperative Group.  Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension and Detection Follow-up Program.  Hypertension.1984;6(suppl I):198-206.Google Scholar
12.
 Heart and Stroke Statistical Update . Dallas, Tex: American Heart Association; 2000.
13.
Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure.  JAMA.1996;275:1557-1562.Google Scholar
14.
Wilson PW. From hypertension to heart failure: what have we learned?  Clin Cardiol.1999;22:V1-V10.Google Scholar
15.
Li K, He H, Li C, Sirois P, Rouleau JL. Myocardial alpha-1-adrenoreceptor: inotropic effect and physiologic and pathologic implications.  Life Sci.1997;60:1305-1318.Google Scholar
16.
Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure.  N Engl J Med.1999;341:1276-1283.Google Scholar
17.
Liebson PR, Grandits GA, Dianzumba S.  et al.  Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS).  Circulation.1995;91:698-706.Google Scholar
18.
Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents.  Circulation.1997;95:2007-2014.Google Scholar
19.
Grimm Jr RH, Flack JM, Schoenberger JA, Gonzalez NM, Liebson PR. Alpha-blockade and thiazide treatment of hypertension: a double-blind randomized trial comparing doxazosin and hydrochlorothiazide.  Am J Hypertens.1996;9:445-454.Google Scholar
20.
Ibsen H, Rasmussen K, Jensen HA, Leth A. Changes in plasma volume and extracellular fluid volume after addition of prazosin to propranolol treatment in patients with hypertension.  Scand J Clin Lab Invest.1978;38:425-429.Google Scholar
21.
Leenen FHH, Smith DL, Faraks RM, Reeves RA, Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive patients.  Am J Med.1987;82:969-978.Google Scholar
22.
White M, Fourney A, Mikes E, Leenen FH. Effect of age and hypertension on cardiac responses to the alpha1-agonist phenylephrine in humans.  Am J Hypertens.1999;12:151-158.Google Scholar
23.
 The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Arch Intern Med.1997;157:2413-2446.Google Scholar
Original Contribution
April 19, 2000

Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Author Affiliations

ALLHAT Officers and Coordinators: Curt D. Furberg, MD, PhD, Jackson T. Wright, MD, PhD, Barry R. Davis, MD, PhD, Jeffrey A. Cutler, MD, MPH, Michael Alderman, MD, Henry Black, MD, William Cushman, MD, Richard Grimm, MD, PhD, L. Julian Haywood, MD, Franz Leenen, MD, Suzanne Oparil, MD, H. Mitchell Perry, MD, Jeffrey Probstfield, MD, Paul Whelton, MD, MSc, Gerald Payne, MD, Chuke Nwachuku, MA, MPH, David Gordon, MD, PhD, Michael Proschan, PhD, Peter Frommer, MD, Paula Einhorn, MD, MS, C. Morton Hawkins, ScD, Charles Ford, PhD, Sara Pressel, MS, Linda Piller, MD, MPH, Christine Lusk, MPH, Judy Bettencourt, Barbara Kimmel, MS, Therese Geraci, MSN, RN, CS, Sandra Walsh, RN, Mahboob Rahman, MD, Anne Juratovac, RN, Robert Pospisil, RN, Kim Brennan, Lillian Carroll, MA, RN, Sheila Sullivan, Gail Barone, RN, Rudell Christian, MPH, Sharon Feldman, MPH, Tracy Lucente, MPH, C. E. Lewis, MD, MSPH, Kim Jenkins, MPH, Peggy McDowell, RN, Janice Johnson, Connie Kingry, RN, BSN, Rebecca Letterer, RN, BSN, Karen Margolis, MD, Leslie Holland, Brenda Jaeger-Fox, Jeffrey Williamson, MD, MHS, Gail Louis, RN, Pamela Ragusa, RN, BSN, Angela Williard, RN, BSN, R. Sue Ferguson, RN, Joanna Tanner, John Eckfeldt, MD, PhD, Richard Crow, MD, John Pelosi, MS.

JAMA. 2000;283(15):1967-1975. doi:10.1001/jama.283.15.1967
Abstract

Context Hypertension is associated with a significantly increased risk of morbidity and mortality. Only diuretics and β-blockers have been shown to reduce this risk in long-term clinical trials. Whether newer antihypertensive agents reduce the incidence of cardiovascular disease (CVD) is unknown.

Objective To compare the effect of doxazosin, an α-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril.

Design Randomized, double-blind, active-controlled clinical trial, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, initiated in February 1994. In January 2000, after an interim analysis, an independent data review committee recommended discontinuing the doxazosin treatment arm based on comparisons with chlorthalidone. Therefore, outcomes data presented herein reflect follow-up through December 1999.

Setting A total of 625 centers in the United States and Canada.

Participants A total of 24,335 patients (aged ≥55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor who received either doxazosin or chlorthalidone.

Interventions Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n=15,268), or doxazosin, 2 to 8 mg/d (n=9067), for a planned follow-up of 4 to 8 years.

Main Outcome Measures The primary outcome measure was fatal CHD or nonfatal myocardial infarction (MI), analyzed by intent to treat; secondary outcome measures included all-cause mortality, stroke, and combined CVD (CHD death, nonfatal MI, stroke, angina, coronary revascularization, congestive heart failure [CHF], and peripheral arterial disease); compared by the chlorthalidone group vs the doxazosin group.

Results Median follow-up was 3.3 years. A total of 365 patients in the doxazosin group and 608 in the chlorthalidone group had fatal CHD or nonfatal MI, with no difference in risk between the groups (relative risk [RR], 1.03; 95% confidence interval [CI], 0.90-1.17; P=.71). Total mortality did not differ between the doxazosin and chlorthalidone arms (4-year rates, 9.62% and 9.08%, respectively; RR, 1.03; 95% CI, 0.90-1.15; P=.56.) The doxazosin arm, compared with the chlorthalidone arm, had a higher risk of stroke (RR, 1.19; 95% CI, 1.01-1.40; P=.04) and combined CVD (4-year rates, 25.45% vs 21.76%; RR, 1.25; 95% CI, 1.17-1.33; P<.001). Considered separately, CHF risk was doubled (4-year rates, 8.13% vs 4.45%; RR, 2.04; 95% CI, 1.79-2.32; P<.001); RRs for angina, coronary revascularization, and peripheral arterial disease were 1.16 (P<.001), 1.15 (P=.05), and 1.07 (P=.50), respectively.

Conclusion Our data indicate that compared with doxazosin, chlorthalidone yields essentially equal risk of CHD death/nonfatal MI but significantly reduces the risk of combined CVD events, particularly CHF, in high-risk hypertensive patients.

×